FDA warns ByHeart that Cronobacter contamination in infant formula and weak investigations led to release of adulterated powdered formula.
What happened
FDA inspected ByHeart's Pennsylvania powdered infant formula base facility from December 21, 2022 through February 17, 2023, and reviewed records from the plant and its third-party contract manufacturers. Investigators found Cronobacter sakazakii in finished product and in many environmental swabs at the plant, and found the company's root cause analyses blamed a laboratory error or isolated events without investigating other likely sources, including water leaks. ByHeart released lots from the same production campaign, then recalled five lots after discussions with FDA.
What FDA found
The company had no process controls covering all stages of production to keep microorganisms out of the formula and the plant.
21 C.F.R. § 106.55(a)After finished product tested positive for Cronobacter sakazakii, the company accepted a root cause analysis blaming lab error even though the outside lab reported that no lab error was found, and did not look at other ways the product could have been contaminated.
21 C.F.R. § 106.55(a)Repeated Cronobacter sakazakii findings in the plant environment were written off as isolated events, without checking water events, employee practices, traffic patterns, or a possible link to product that tested positive.
21 C.F.R. § 106.55(a)Two leaks of outside water into manufacturing areas, one through a skylight and one at the dryer tower, were never evaluated as possible causes of the contamination.
21 C.F.R. § 106.55(a)The company released other lots from the same continuous production campaign without weighing the sanitation breaks, so adulterated infant formula went into U.S. commerce.
Section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)]The company did not tell FDA when infant formula that may have been adulterated left its control for distribution.
21 C.F.R. § 106.150; section 412(e)(1)(B) of the Act [21 U.S.C. § 350a(e)(1)(B)]
What FDA wants
FDA tells ByHeart to reply within fifteen working days with the specific steps taken to correct each violation, including how it will find and prevent similar problems, plus supporting documents. If corrections cannot be finished in that time, the company must say why and give a completion date.
Who should pay attention
- infant formula brand owners that rely on contract manufacturers
- contract manufacturers that blend and pack powdered infant formula
- quality teams running environmental monitoring and root cause analysis in low-moisture food plants
This is a summary. Read the original letter on fda.gov.